FP407EVALUATION OF THE GLOMERULAR HEMODYNAMICS BY THE SGLT2 INHIBITOR EMPAGLIFLOZIN USING IN VIVO IMAGING

Authors:

Abstract
INTRODUCTION AND AIMS: In the EMPA-REG outcome trial, Empagliflozin (Empa), a sodium-glucose cotransporter 2 inhibitor, slowed the progression of diabetic kidney disease (DKD) in patients with type 2 diabetes. Improvement of glomerular hyperfiltration via tubuloglomerular feedback (TGF) is considered to be one of the possible pathways for renal protection with SGLT2 inhibition (SGLT2i) in diabetic kidney disease (DKD). However, the mechanisms that regulate renal function in response to SGLT2i have not been fully elucidated. We explored the renal protective mechanisms of SGLT2i with empagliflozin (EMPA), with a focus on glomerular hemodynamic effects and TGF using in vivo multiphoton microscope (MPM) imaging techniques.